Research Article

You have full text access to this OnlineOpen article

Gabapentin in the treatment of fibromyalgia: A randomized, double-blind, placebo-controlled, multicenter trial

  1. Lesley M. Arnold1,‡,*,
  2. Don L. Goldenberg2,
  3. Sharon B. Stanford1,
  4. Justine K. Lalonde3,†,
  5. H. S. Sandhu2,
  6. Paul E. Keck Jr.1,§,
  7. Jeffrey A. Welge1,
  8. Fred Bishop1,
  9. Kevin E. Stanford1,
  10. Evelyn V. Hess1,
  11. James I. Hudson3

Article first published online: 28 MAR 2007

DOI: 10.1002/art.22457

Issue

Arthritis & Rheumatism

Arthritis & Rheumatism

Volume 56, Issue 4, pages 1336–1344, April 2007

Additional Information

How to Cite

Arnold, L. M., Goldenberg, D. L., Stanford, S. B., Lalonde, J. K., Sandhu, H. S., Keck, P. E., Welge, J. A., Bishop, F., Stanford, K. E., Hess, E. V. and Hudson, J. I. (2007), Gabapentin in the treatment of fibromyalgia: A randomized, double-blind, placebo-controlled, multicenter trial. Arthritis & Rheumatism, 56: 1336–1344. doi: 10.1002/art.22457

Author Information

  1. 1

    University of Cincinnati College of Medicine, Cincinnati, Ohio

  2. 2

    Newton-Wellesley Hospital, Newton, Massachusetts, and Tufts University School of Medicine, Boston, Massachusetts

  3. 3

    McLean Hospital, Belmont, Massachusetts, and Harvard Medical School, Boston, Massachusetts

  1. †

    AstraZeneca Pharmaceuticals, Zug, Switzerland

  1. ‡

    Dr. Arnold has received consulting fees from Eli Lilly (more than $10,000) and from Pfizer, Cypress Bioscience, Wyeth Pharmaceuticals, Sanofi-Aventis, Boehringer Ingelheim, Sepracor, Forest Laboratories, Allergan, and Vivus (less than $10,000 each). She also has received research support from Eli Lilly, Pfizer, Cypress Bioscience, Wyeth Pharmaceuticals, Sanofi-Aventis, and Boehringer Ingelheim.

  2. §

    Dr. Keck has received consulting fees (less than $10,000) from or is a member of the scientific advisory boards of Abbott, AstraZeneca Pharmaceuticals, Bristol-Myers Squibb, GlaxoSmithKline, Eli Lilly, and Pfizer. He is a principal or coinvestigator on research studies sponsored by Abbott, the American Diabetes Association, AstraZeneca Pharmaceuticals, Bristol-Myers Squibb, GlaxoSmithKline, Eli Lilly, Janssen Pharmaceutica, the National Institute of Mental Health, the National Institute of Drug Abuse, Pfizer, the Stanley Medical Research Institute, and UCB.

*University of Cincinnati Medical Arts Building, 222 Piedmont Avenue, Suite 8200, Cincinnati, OH 45219

Publication History

  1. Issue published online: 28 MAR 2007
  2. Article first published online: 28 MAR 2007
  3. Manuscript Accepted: 19 DEC 2006
  4. Manuscript Received: 29 AUG 2006

Funded by

  • National Institute of Arthritis and Musculoskeletal and Skin Diseases. Grant Number: N01-AR-2-2264

SEARCH

SEARCH BY CITATION

ARTICLE TOOLS

View Full Article (HTML) Get PDF (168K)

REFERENCES

  • 1
    Wolfe F, Smythe HA, Yunus MB, Bennett RM, Bombardier C, Goldenberg DL, et al. The American College of Rheumatology 1990 criteria for the classification of fibromyalgia: report of the Multicenter Criteria Committee. Arthritis Rheum 1990; 33: 160–72.
    Direct Link:
  • 2
    Hudson JI, Pope HG Jr. The relationship between fibromyalgia and major depressive disorder [review]. Rheum Dis Clin North Am 1996; 22: 285–303.
  • 3
    Wolfe F, Ross K, Anderson J, Russell IJ, Hebert L. The prevalence and characteristics of fibromyalgia in the general population. Arthritis Rheum 1995; 38: 19–28.
    Direct Link:
  • 4
    Pillemer SR, Bradley LA, Crofford LJ, Moldofsky H, Chrousos GP. The neuroscience and endocrinology of fibromyalgia. Arthritis Rheum 1997; 40: 1928–39.
    Direct Link:
  • 5
    Lautenbacher S, Rollman GB. Possible deficiencies of pain modulation in fibromyalgia. Clin J Pain 1997; 13: 189–96.
  • 6
    Bennett RM. Emerging concepts in the neurobiology of chronic pain: evidence of abnormal sensory processing in fibromyalgia [review]. Mayo Clin Proc 1999; 74: 385–98.
  • 7
    Staud R. Evidence of involvement of central neural mechanisms in generating fibromyalgia pain [review]. Curr Rheumatol Rep 2002; 4: 299–305.
  • 8
    Baranauskas G, Nistri A. Sensitization of pain pathways in the spinal cord: cellular mechanisms [review]. Prog Neurobiol 1998; 54: 349–65.
  • 9
    Rowbotham MC. Is fibromyalgia a neuropathic pain syndrome? [review]. J Rheumatol Suppl 2005; 75: 38–40.
  • 10
    Woolf CJ. Pain: moving from symptom control toward mechanism-specific pharmacologic management [review]. Ann Intern Med 2004; 140: 441–51.
  • 11
    Crofford LJ. The relationship of fibromyalgia to neuropathic pain syndromes [review]. J Rheumatol Suppl 2005; 75: 41–5.
  • 12
    Pan HL, Eisenach JC, Chen SR. Gabapentin suppresses ectopic nerve discharges and reverses allodynia in neuropathic rats. J Pharmacol Exp Ther 1999; 288: 1026–30.
  • 13
    Hao JX, Xu XJ, Urban L, Wiesenfeld-Hallin Z. Repeated administration of systemic gabapentin alleviates allodynia-like behaviors in spinally injured rats. Neurosci Lett 2000; 280: 211–4.
  • 14
    Abdi S, Lee DH, Chung JM. The anti-allodynic effects of amitriptyline, gabapentin, and lidocaine in a rat model of neuropathic pain. Anesth Analg 1998; 87: 1360–6.
  • 15
    Taylor CP, Gee NS, Su TZ, Kocsis JD, Welty DF, Brown JP, et al. A summary of mechanistic hypotheses of gabapentin pharmacology [review]. Epilepsy Res 1998; 29: 233–49.
  • 16
    Urban MO, Ren K, Park KT, Campbell B, Anker N, Stearns B, et al. Comparison of the antinociceptive profiles of gabapentin and 3-methylgabapentin in rat models of acute and persistent pain: implications for mechanism of action. J Pharmacol Exp Ther 2005; 313: 1209–16.
  • 17
    Backonja M, Beydoun A, Edwards KR, Schwartz SL, Fonseca V, Hes M, et al. Gabapentin for the symptomatic treatment of painful neuropathy in patients with diabetes mellitus: a randomized controlled trial. JAMA 1998; 280: 1831–6.
  • 18
    Morello CM, Leckband SG, Stoner CP, Moorhouse DF, Sahagian GA. Randomized double-blind study comparing the efficacy of gabapentin with amitriptyline on diabetic peripheral neuropathy pain. Arch Intern Med 1999; 159: 1931–7.
  • 19
    Rowbotham M, Harden N, Stacey B, Bernstein P, Magnus-Miller L. Gabapentin for the treatment of postherpetic neuralgia: a randomized controlled trial. JAMA 1998; 280: 1837–42.
  • 20
    Rice AS, Maton S, Postherpetic Neuralgia Study Group. Gabapentin in postherpetic neuralgia: a randomised, double blind, placebo controlled study. Pain 2001; 94: 215–24.
  • 21
    Mathew NT, Rapoport A, Saper J, Magnus L, Klapper J, Ramadan N, et al. Efficacy of gabapentin in migraine prophylaxis. Headache 2001; 41: 119–28.
    Direct Link:
  • 22
    Backonja M, Glanzman RL. Gabapentin dosing for neuropathic pain: evidence from randomized, placebo-controlled clinical trials [review]. Clin Ther 2003; 25: 81–104.
  • 23
    Pande AC, Davidson JR, Jefferson JW, Janney CA, Katzelnick DJ, Weisler RH, et al. Treatment of social phobia with gabapentin: a placebo-controlled study. J Clin Psychopharmacol 1999; 19: 341–8.
  • 24
    Pande AC, Pollack MH, Crockatt J, Greiner M, Chouinard G, Lydiard RB, et al. Placebo-controlled study of gabapentin treatment of panic disorder. J Clin Psychopharmacol 2000; 20: 467–71.
  • 25
    Foldvary-Schaefer N, De Leon Sanchez I, Karafa M, Mascha E, Dinner D, Morris HH. Gabapentin increases slow-wave sleep in normal adults. Epilepsia 2002; 43: 1493–7.
    Direct Link:
  • 26
    Cleeland CS, Ryan KM. Pain assessment: global use of the Brief Pain Inventory [review]. Ann Acad Med Singapore 1994; 23: 129–38.
  • 27
    Fisher LD, Dixon DO, Herson J, Frankowski RK, Hearron MS, Peace KE. Intention to treat in clinical trials. In: PeaceKE, editor. Statistical issues in drug research and development. New York: Marcel Dekker; 1990. p. 331–50.
  • 28
    Ware JH. Interpreting incomplete data in studies of diet and weight loss. N Engl J Med 2003; 348: 2136–7.
  • 29
    Burckhardt CS, Clark SR, Bennett RM. The Fibromyalgia Impact Questionnaire: development and validation. J Rheumatol 1991; 18: 728–33.
  • 30
    Fischer AA. Pressure threshold meter: its use for quantification of tender spots. Arch Phys Med Rehabil 1986; 67: 836–8.
  • 31
    Guy W. ECDEU assessment manual for psychopharmacology, revised. US Department of Health, Education, and Welfare publication (ADM). Rockville (MD): National Institute of Mental Health; 1976. p. 76–338.
  • 32
    Hays RD, Stewart AL. Sleep measures. In: StewartAL, WareJE, editors. Measuring functioning and well-being. Durham (NC): Duke University Press; 1992. p. 232–59.
  • 33
    Montgomery SA, Asberg M. A new depression scale designed to be sensitive to change. Br J Psychiatry 1979; 134: 382–9.
  • 34
    Ware JE, Snow KK, Kosinski M, Gandek B. SF-36 health survey manual and interpretation guide. Boston: The Health Institute, New England Medical Center; 1993.
  • 35
    Sheehan DV, Lecrubier Y, Sheehan KH, Amorim P, Janavs J, Weiller E, et al. The Mini-International Neuropsychiatric Interview (M.I.N.I.): the development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10 [review]. J Clin Psychiatry 1998; 59 Suppl 20: 22–33.
  • 36
    American Psychiatric Association. Diagnostic and statistical manual of mental disorders, 4th edition Washington, DC: American Psychiatric Association; 1994.
  • 37
    Arnold LM, Hess EV, Hudson JI, Welge JA, Berno SE, Keck PE Jr. A randomized, placebo-controlled, double-blind, flexible-dose study of fluoxetine in the treatment of women with fibromyalgia. Am J Med 2002; 112: 191–7.
  • 38
    Gibbons RD, Hedeker D, Elkin I, Waternaux C, Kraemer HC, Greenhouse JB, et al. Some conceptual and statistical issues in analysis of longitudinal psychiatric data: application to the NIMH Treatment of Depression Collaborative Research Program dataset. Arch Gen Psychiatry 1993; 50: 739–50.
  • 39
    Fitzmaurice GM, Laird NM, Ware JH. Applied longitudinal analysis. Hoboken (NJ): John Wiley & Sons; 2004.
  • 40
    Farrar JT, Young JP Jr, LaMoreaux L, Werth JL, Poole RM. Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale. Pain 2001; 94: 149–58.
  • 41
    Arnold LM, Keck PE Jr, Welge JA. Antidepressant treatment of fibromyalgia: a meta-analysis and review. Psychosomatics 2000; 41: 104–13.
  • 42
    Arnold LM, Rosen A, Pritchett YL, D'Souza DN, Goldstein DJ, Iyengar S, et al. A randomized, double-blind, placebo-controlled trial of duloxetine in the treatment of women with fibromyalgia with or without major depressive disorder. Pain 2005; 119: 5–15.
  • 43
    Crofford LJ, Rowbotham MC, Mease PJ, Russell IJ, Dworkin RH, Corbin AE, et al, for the Pregabalin 1008-105 Study Group. Pregabalin for the treatment of fibromyalgia syndrome: results of a randomized, double-blind, placebo-controlled trial. Arthritis Rheum 2005; 52: 1264–73.
    Direct Link:
View Full Article (HTML) Get PDF (168K)